Converting skin biology to novel treatment paradigms

MC2 Therapeutics is a commercial stage pharmaceutical company committed to research in skin biology and development of novel treatment paradigms for people with autoimmune and chronic inflammatory skin conditions.

Our innovative approach to address complex challenges more effectively is anchored in deep understanding of the skin biology combined with learnings from the pathophysiology across disease segments. Fueled by an entrepreneurial mindset and creativity, MC2 Therapeutics aims to set new standards in treatment satisfaction for people with skin conditions.

Our breakthrough discovery of a novel biological paradigm for treatment of urea associated skin diseases is a prime example of the impact of this approach, which is manifested in our drug candidates for Chronic Kidney Disease associated Pruritus and for Lichen Sclerosus. Wynzora® Cream (marketed in US and EU) for plaque psoriasis in adults is an example of how our proprietary formulation and drug delivery system PAD Technology™ enables a new standard of topical therapy.

MC2 Therapeutics remains focused on a high-performance culture and expertise to provide a strong basis for pursuing strategic optionality with the purpose of broadening our business and build momentum as we grow into a fully integrated biopharmaceutical company.

Read more about PAD™ based Wynzora® Cream drug for treatment of plaque psoriasis in adults here.

Read more about our pipeline of PAD™ based drug candidates here.


We are committed to convert skin biology into novel treatment paradigms and redefining the treatment experience within auto-immune and chronic inflammatory skin conditions.

Read more about our platform, pipeline and purpose in our corporate presentation.